PRASAD-CORP/CUBE-TEC
20.12.2022 10:31:39 CET | Business Wire | Press release
Prasad Corp, the world leader in film preservation, digitization, and restoration, has formed a strategic partnership with Cube-Tec International, Germany and will exclusively represent Cube-Tec’s QUADRIGA INSPECTIONscan.one technology in some of the world’s leading and largest archival markets, including North America and India.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221219005315/en/
Cube-Tec develops integrated solutions for large media archives and is a pioneer in quality control media workflows for Film and Video. QUADRIGA INSPECTIONscan.one enables the sustainable safeguarding of large film collections. It offers the possibility of digitizing film material in its original state in mezzanine quality.
Prasad will continue to consult, advise and provide global archives with its full spectrum preservation solutions, which are a unique combination of technology and services, thereby enabling archives to #preserve4posterity.
“As the global markets return to normalcy, global archives are increasingly looking for intelligent archival solutions driven by the latest technologies to preserve their valuable assets. I am very excited to share with you this strategic partnership with Cube-Tec which I believe will be a great value-add to our customers, viz, Archives, Content owners, Content aggregators, and the like, worldwide,” says Saiprasad, Director - Prasad Corp.
“Providing Digital Twins for complete film collections without the time-consuming prep work is a breakthrough technology. Combined with the automation of labour-intensive film inspection and reporting, INSPECTIONscan users can make fact-based preservation decisions for each film reel with minimal effort. The strategic partnership with Prasad will enable more archives to benefit quickly from this new technology,” Jörg Houpert, Head of Technology - Cube-Tec International.
About Prasad Corp:
Prasad Corp offers a comprehensive range of preservation, digitization, and restoration services globally. As the proud owner of Digital Film Technology GmbH, a manufacturer of Motion Picture Film Scanners, Prasad is uniquely positioned to offer convenient, strategic, and wholesome preservation services to its customers both onsite and offsite.
For more visit – www.prasadcorp.com
About Cube-Tec International:
Cube-Tec International develops integrated solutions for large media archives. As a pioneer in quality control of media workflows, the company focuses on open standards and agile process automation. Cube-Tec benefits from a great deal of experience with large-scale media digitization projects.
For more visit - https://www.cube-tec.com/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005315/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom